Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Risedronate: a new oral bisphosphonate.

E M Umland1, E G Boyce

  • 1Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, Pennsylvania 19104, USA.

Clinical Therapeutics
|October 9, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of Second-line Drugs on the Progression or Regression of Rheumatoid Nodules.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2008
Same author

Sildenafil citrate: a therapeutic update.

Clinical therapeutics·2001
Same author

Phytoestrogens as therapeutic alternatives to traditional hormone replacement in postmenopausal women.

Pharmacotherapy·2000
Same author

The impact of estrogen replacement therapy and raloxifene on osteoporosis, cardiovascular disease, and gynecologic cancers.

The Annals of pharmacotherapy·2000
Same author

Cardiovascular effects of troglitazone.

The Annals of pharmacotherapy·1999
Same author

Potential risk factors associated with thrombocytopenia in a surgical intensive care unit.

Pharmacotherapy·1999
Same journal

Combined Effects of Nicorandil and Enhanced External Counterpulsation on Coronary Microcirculation and Exercise Capacity in Patients With Coronary Slow Flow Phenomenon: A Randomized, Controlled, 3-Arm Trial.

Clinical therapeutics·2026
Same journal

Phase 1 Study Evaluating Gefurulimab Pharmacokinetics and Safety Following Delivery Via Autoinjector or Prefilled Syringe With Needle Safety Device in Healthy Adults.

Clinical therapeutics·2026
Same journal

Evaluating Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Associated With Newer Antiseizure Medications Using FAERS and JADER Combined With Bioinformatics Exploration.

Clinical therapeutics·2026
Same journal

Diversity: A Medical Research Imperative.

Clinical therapeutics·2026
Same journal

LOARGYS (pegzilarginase-nbln).

Clinical therapeutics·2026
Same journal

A Phase I Study Assessing the Safety, Tolerability, and Pharmacokinetics of Yinfenidone: A Novel, Potent Drug for Idiopathic Pulmonary Fibrosis Treatment in Healthy Chinese Subjects.

Clinical therapeutics·2026
See all related articles

Risedronate effectively treats osteoporosis and Paget's disease, showing comparable efficacy to alendronate but with better gastrointestinal tolerability. Further studies are needed to define its optimal role in bone disease therapy.

Area of Science:

  • Pharmacology and Therapeutics
  • Bone Metabolism and Disease

Background:

  • Bisphosphonates are established treatments for osteoporosis and Paget's disease.
  • Risedronate is a newer oral bisphosphonate approved for postmenopausal and glucocorticoid-induced osteoporosis, and Paget's disease.

Purpose of the Study:

  • To review current studies on risedronate for osteoporosis and Paget's disease.
  • To compare risedronate with other bisphosphonates and therapies.
  • To review risedronate's pharmacokinetics, adverse effects, and use in other disorders.

Main Methods:

  • Searches of MEDLINE, PREMEDLINE, and International Pharmaceutical Abstracts (1966-2000).
  • Inclusion of English-language clinical studies and review articles.
  • Use of search terms: risedronate, NE 58095, bisphosphonates, alendronate, osteoporosis, Paget's disease.

Related Experiment Videos

Main Results:

  • Risedronate increases bone mineral density (BMD) and reduces fractures in postmenopausal osteoporosis.
  • In glucocorticoid-induced osteoporosis, risedronate increases BMD but fracture risk reduction is inconsistent.
  • Risedronate shows potential advantages over etidronate and alendronate regarding BMD, fracture risk, and gastrointestinal tolerability.

Conclusions:

  • Risedronate is comparable to alendronate for osteoporosis and Paget's disease treatment efficacy.
  • Risedronate may be preferred over alendronate due to better gastrointestinal tolerability.
  • Further comparative and pharmacoeconomic studies are required to establish risedronate's definitive therapeutic position.